Financial Transparency & Efficiency of the Prescription Drug, Biosimilar, & Generic Drug User Fees

Why It Matters

The disclosed financial outlook and capacity‑planning updates shape future user‑fee levels and review timelines, directly affecting drug developers' budgeting and market entry strategies.

Key Takeaways

• PDUFA 7 projected budget for FY26 reaches $1.99 billion.
• BaSUFA 3 expects $86 million resources, $52 million obligations FY26.
• GDUFA 3 forecasts $821 million resources, $611.6 million obligations FY26.
• Operating reserve adjustments may alter FY27 fee targets across programs.
• Resource capacity planning now supports staffing without increasing user fee revenues.

Summary

The FDA held its annual public meeting to detail financial transparency and efficiency of the Prescription Drug User Fee Act (PDUFA 7), Biosimilar User Fee Act (BaSUFA 3), and Generic Drug User Fee Amendments (GDUFA 3). CFO Benjamin Mons opened the session, emphasizing the agency’s commitment under the 2022 user‑fee reauthorization to improve budgeting, reporting, and resource use.

Presenters outlined five‑year financial plans, providing actuals for FY23‑25 and projections for FY26‑27. PDUFA 7 is slated to command roughly $1.99 billion in FY26 resources, with $496 million net carryover after obligations. BaSUFA 3 anticipates $86 million in resources and $33 million carryover, while GDUFA 3 projects $821 million in resources and $203.8 million carryover. All programs assume net collections meet target revenues, though operating‑reserve adjustments could shift FY27 fee targets if carryover deviates from statutory ranges.

Josh Barton highlighted the evolution of resource capacity planning, noting that the capability has moved from a concept in 2019 to an integrated operational tool. He cited technical upgrades, distinct models for complex and non‑complex ANDAs, and ongoing staffing efforts that aim to meet review workloads without raising user‑fee revenues. The meeting concluded with a call for public comments via docket FDA‑2026‑N‑3273, underscoring the FDA’s intent to incorporate stakeholder feedback.

For industry participants, the disclosed budgets and obligations signal the scale of FDA’s review capacity and potential fee adjustments in upcoming cycles. Understanding the projected carryover balances and the conditions that trigger operating‑reserve changes helps pharmaceutical companies anticipate cost structures and plan regulatory strategies accordingly.

Original Description

The FDA Financial Public Meeting is held annually to update interested public stakeholders on topics related to the financial management of the Prescription Drug User Fee Act (PDUFA) VII, Biosimilar User Fee Act (BsUFA) III, and Generic Drug User Fee Amendments (GDUFA) III.